askwala.com - Scientists Discover Brain Chemical Linked to Depression and Suicidal Thoughts
Header







Scientists Discover Brain Chemical Linked to Depression and Suicidal Thoughts

Image name: Very-Depressed-Man-Close-Up-777x518.jpg

✨ Neuroscientists at Columbia and McGill have uncovered that elevated levels of a stress-related brain chemical, SGK1, may be the missing link between childhood trauma and adult depression or suicidal thoughts. Credit: Shutterstock.

🔵 A brain chemical called SGK1 may explain why childhood trauma increases depression risk. Blocking it could lead to better antidepressants.

Neuroscientists from Columbia University and McGill University have identified a brain chemical that may explain why people who experienced trauma or adversity in childhood are more prone to depression and suicidal thoughts.

Their findings reveal that elevated levels of a stress-related chemical called SGK1 contribute to these mental health risks. The discovery opens the door to a new kind of antidepressant that targets and inhibits SGK1, offering potential relief for individuals who suffered abuse or neglect early in life. Studies show that about 60% of U.S. adults with major depression and nearly two-thirds of those who attempt suicide report some form of childhood adversity or trauma.

“Current antidepressants are often less effective for people with a history of childhood adversity, who represent a large proportion of adults with depression,” says the study’s leader, Christoph Anacker, assistant professor of clinical neurobiology in the Department of Psychiatry at Columbia University Vagelos College of Physicians and Surgeons. “What’s exciting about our study is that it raises the prospect of quickly developing new treatments, as SGK1 inhibitors are in development for other conditions, and gives us a screening tool to identify people at greatest risk.”

🔵 Depression triggered by early life adversity is different

Experiencing hardship in childhood—from family dysfunction to physical abuse—is among the strongest predictors of depression in adulthood.

Although SSRI antidepressants are widely used and effective for many individuals with depression or anxiety, they often fall short in treating those with a history of early trauma. “This suggested to us that the biological processes that lead to depression and suicidality in general may differ from those with less stressful childhoods,” Anacker notes.

Roughly a decade ago, while investigating the biological mechanisms behind this difference, Anacker and his colleagues discovered elevated SGK1 levels in the blood of patients with depression who had not yet received medication.

In the new study, the researchers found high levels of the chemical in the brains of adults who died by suicide, with the highest levels (up to twice as much as other patients who died by suicide) in those who had experienced childhood trauma. They also found that children exposed to early life adversity who possessed gene variants that increase SGK1 in the brain were more likely to develop depression as teenagers, suggesting that the chemical is a catalyst for depression and suicidal behavior.

➡️ A new antidepressant?

Anacker says drugs that inhibit SGK1 may have the potential to prevent or treat depression in people exposed to childhood trauma, based on the study’s findings in mice. In those experiments, an SGK1 inhibitor injected into the bloodstream prevented the development of depressive behaviors in mice experiencing chronic stress.

SGK1 inhibitors are being tested in people with atrial fibrillation and other conditions, and Anacker’s team is now looking to begin testing SGK1 inhibitors in people with depression and a history of childhood adversity. The study also suggests that individuals with depression and early life trauma could undergo genetic screening to determine if they may be most likely to benefit from an SGK1 antidepressant.

“There’s an urgent need to identify and treat people with the greatest risk of depression and suicide after exposure to early life adversity and SGK1 is a promising avenue to explore,” Anacker says. 




© Columbia University Irving Medical Center   













Short info

× Chat